OSR Holdings, Inc. OSRH · Stock Open OSR Holdings, Inc. in new tab
OSR Holdings, Inc. Analysis (OSRH)
Is OSR Holdings, Inc. a good investment? OSR Holdings, Inc. (OSRH) is currently trading at 0.2200 USD.
In terms of valuation, the stock trades at a P/E ratio of 9.63. This relatively low multiple may signal that OSR Holdings, Inc. is undervalued compared to historical market norms.
Earnings Schedule: OSR Holdings, Inc. is expected to release its next earnings report on Dec. 2, 2026.
Investor FAQ
Does OSR Holdings, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is OSR Holdings, Inc.?
OSR Holdings, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Dec. 2, 2026. The company currently has a trailing EPS of -0.37.
Company Profile
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
Community Discussion